KSI-501's DAYBREAK Phase 3 readout will determine whether Kodiak's bispecific platform extends beyond Zenkuda's DR success into the crowded wet AMD market

Bull

A positive outcome would require KSI-501 to demonstrate superiority or non-inferiority to Zenkuda on mean BCVA gain with a favorable durability or anatomical dryness profile, ideally showing deeper fluid resolution or longer injection intervals attributable to the IL-6 inhibition component. This would confirm that dual pathway blockade adds clinically meaningful benefit over anti-VEGF alone in wet AMD, validating the bispecific architecture and opening a large commercial opportunity alongside Zenkuda.

Bear

The most likely failure mode is that KSI-501 shows no incremental benefit over Zenkuda in BCVA or fluid outcomes, suggesting that IL-6 co-inhibition does not meaningfully drive wet AMD pathology beyond VEGF, which would undermine the bispecific rationale in this indication. A second risk is a safety signal — particularly intraocular inflammation from the IL-6 component — that narrows the benefit-risk profile versus the clean Zenkuda safety record already demonstrated in GLOW2.